I. Baladrón

发表

CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.

Y. Perera, S. Perea, I. Baladrón, 2018, Seminars in oncology.

CIGB-300: A Promising Anti-Casein Kinase 2 (CK2) Peptide for Cancer Targeted Therapy

D. Alonso, Y. Perera, S. Perea, 2015 .

CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research

D. Gomez, D. Alonso, Y. Perera, 2011, Molecular and Cellular Biochemistry.

CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo

D. Alonso, O. Mendoza, Y. Perera, 2008, Molecular and Cellular Biochemistry.

Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies

D. Alonso, P. López-Saura, S. Perea, 2009, BMC Cancer.

Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial

Y. Perera, G. Guillén, Ariadna Garcia, 2020, medRxiv.

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine ( CIGB-228 ) inWomen with High-Grade Cervical Intraepithelial Neoplasia : First-inHuman , Proof-of-Concept Trial

P. López-Saura, A. Ferrer, I. Torréns, 2014 .

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial

P. López-Saura, A. Ferrer, I. Torréns, 2011, ISRN obstetrics and gynecology.

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer

D. Alonso, A. Perera, P. López-Saura, 2015, British Journal of Cancer.

Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac

R. Bringas, G. Guillén, L. E. Fernández, 2019, Front. Oncol..